Structure Therapeutics Inc ADR
GPCRHealthcare·Biotechnology·USA·Small·NASD·Nov 13 • 7:01 AM ET
19.92+0.08 (0.40%)
2026-11-13 13:07 CET
Market cap
$1.42B
Revenue, TTM
0.00 USD m
Net income, TTM
-294.52 USD m
Free cash flow, TTM
-278.01 USD m
EPS diluted, TTM
-3.95
Price
GPCR against its 20, 50 and 200-day averagesPatternshover a marker to name it
79.0% under the 52-week high of 94.90 on 8 Dec 2025. 52-week low 18.70 on 6 Nov 2026. Last 15 sessions, 21.5% high to low
Volume 0.02× normal · the line is the 50-bar volume average
Setup. RS line 0
CANSLIM 2 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High; Performance: Year +50%
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 1 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 0 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 2 of 5 — fails: Return on Equity: Over +15% — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 2 of 4 — fails: Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 2 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 1 of 4 — fails: Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 1 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200
Profile
GPCR52-week range, 2% of the way up
18.7094.90
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.
| Employees | 220 |
|---|---|
| IPO | Feb 03, 2023 |
| Beta | -1.16 |
| ATR, 14d | 1.43 |
| Rel volume | 0.02 |
| Short float | 8.53% |
| Insider own | 2.60% |
| Inst own | 91.12% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | $1.42B |
| Enterprise Value | 188.37M |
| Income | -294.52M |
| Sales | 0.00M |
| Book / share | 17.12 |
| Cash / share | 17.38 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 220 |
| IPO | Feb 03, 2023 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | - |
| Price / book | 1.16 |
| Price / cash | 1.15 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | - |
| Quick Ratio | 11.91 |
| Current Ratio | 11.91 |
| Debt / equity | 0.01 |
| Long-term debt / equity | 0.00 |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -3.95 |
|---|---|
| Earnings next year | -2.59 |
| Earnings next quarter | -0.67 |
| Earnings this year | -164.88% |
| Earnings next year | -22.38% |
| Earnings growth, 5 years | - |
| Past earnings growth | -18.36% -40.35% |
| Past sales growth | - - |
| Earnings vs last year | -8.08% |
| Sales vs last year | - |
| Earnings vs last quarter | -77.07% |
| Sales vs last quarter | - |
| Earnings | Nov 09 AMC |
| Surprise | 0.00% - |
Ownership
| Insiders own | 2.60% |
|---|---|
| Insider trades | 0.00% |
| Institutions own | 91.12% |
| Institution trades | -0.03% |
| Return on assets | -27.19% |
| Return on equity | -29.57% |
| Return on capital | -24.02% |
| Gross Margin | - |
| Operating margin | - |
| Profit Margin | - |
| 20-day average | -5.69% |
| 50-day average | -28.56% |
| 200-day average | -56.32% |
Technical
| Shares out | 71.36M |
|---|---|
| Shares floating | 69.51M |
| Short / float | 8.53% |
| Short ratio | 5.15 |
| Short interest | 5.93M |
| 52-week high | 94.90 -79.0% |
| 52-week low | 18.70 +6.5% |
| Volatility | 8.55% 6.60% |
| Average range | 1.43 |
| Strength index | 32.57 |
| Market sensitivity | -1.16 |
| Relative volume | 0.02 |
| Avg Volume | 1.15M |
| Volume | 1,076 |
Performance
| Perf Week | -2.11% |
|---|---|
| Perf Month | -10.23% |
| Perf Quarter | -62.95% |
| Perf Half Y | -48.51% |
| Perf YTD | -71.36% |
| Perf Year | -43.09% |
| Perf 3Y | -63.56% |
| Perf 5Y | - |
| Perf 10Y | - |
| Recommendation | 1.12 |
| Target Price | 105.07 |
| Prev Close | 19.84 |
| Price | 19.92 |
| Change % | 0.40% |
Analyst ratings
latest 10 of 16| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Apr 27, 2026 | Initiated | Canaccord Genuity | Buy | $101 | +407.0% |
| Mar 26, 2026 | Initiated | Wolfe Research | Peer Perform | ||
| May 02, 2025 | Initiated | Citigroup | Buy | $60 | +201.2% |
| Feb 28, 2025 | Initiated | William Blair | Outperform | ||
| Jan 08, 2025 | Initiated | Stifel | Buy | $50 | +151.0% |
| Dec 04, 2024 | Initiated | H.C. Wainwright | Buy | $80 | +301.6% |
| Sep 23, 2024 | Initiated | Morgan Stanley | Overweight | $118 | +492.4% |
| May 21, 2024 | Initiated | JP Morgan | Overweight | $65 | +226.3% |
| Apr 09, 2024 | Initiated | Cantor Fitzgerald | Overweight | $65 | +226.3% |
| Oct 19, 2023 | Initiated | JMP Securities | Mkt Outperform | $90 | +351.8% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| VKTX | Viking Therapeutics Inc | 3.57B |
| KLRA | Kailera Therapeutics Inc | 1.72B |
| SEPN | Septerna Inc | 1.99B |
| ALT | Altimmune Inc | 315.12M |
| LLY | Lilly(Eli) & Co | 1340.68B |
| NVO | Novo Nordisk ADR | 135.81B |
| MDGL | Madrigal Pharmaceuticals Inc | 9.91B |
| MLYS | Mineralys Therapeutics Inc | 1.37B |
| RYTM | Rhythm Pharmaceuticals Inc | 7.62B |
| AMGN | AMGEN Inc | 253.15B |
Insider trading
7 filings| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| BLAS COLL CRESPO | Officer | Sep 21 '26 | Proposed Sale | 35.00 | 4,008 | 140,280 | Sep 21 04:35 PM | |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Sep 01 '26 | Option Exercise | 0.34 | 17,817 | 6,058 | 246,777 | Sep 02 09:18 PM |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Aug 18 '26 | Option Exercise | 0.34 | 11,817 | 4,018 | 240,777 | Aug 19 08:23 PM |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Aug 04 '26 | Option Exercise | 0.34 | 11,817 | 4,018 | 240,777 | Aug 05 04:49 PM |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Jul 14 '26 | Option Exercise | 0.34 | 23,634 | 8,036 | 252,594 | Jul 15 06:57 PM |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Jun 25 '26 | Option Exercise | 0.34 | 23,634 | 8,036 | 252,594 | Jun 29 08:32 PM |
| XICHEN LIN | Officer | Jun 25 '26 | Proposed Sale | 48.16 | 35,512 | 1,710,258 | Jun 25 04:27 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| IBB | iShares Biotechnology ETF | AUM: 11.39B |
| SBIO | ALPS Medical Breakthroughs ETF | AUM: 195.04M |
| SPEM | State Street SPDR Portfolio Emerging Markets ETF | AUM: 16.56B |
| FDG | American Century Focused Dynamic Growth ETF | AUM: 432.58M |
| OZEM | Roundhill GLP-1 & Weight Loss ETF | AUM: 58.25M |
| LRNZ | TrueShares Technology, AI & Deep Learning ETF | AUM: 38.40M |
| ONEQ | Fidelity Nasdaq Composite Index ETF | AUM: 10.51B |
| GXC | State Street SPDR S&P China ETF | AUM: 439.74M |
| APIE | ActivePassive International Equity ETF | AUM: 1.14B |
| FMED | Fidelity Disruptive Medicine ETF | AUM: 30.30M |
News
latest 14 of 200- Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights (GlobeNewswire) +5.21%
- Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
- Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek 2026 (GlobeNewswire)
- Entera Bio Receives New Overweight Rating From Cantor Fitzgerald (NASDAQ: ENTX) (FinanceWire)
- VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 Multi-Blockbusters (Stocktwits)
- Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management (GlobeNewswire) -14.70%
- Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences (GlobeNewswire)
- Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights (GlobeNewswire)
- Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy. (MarketWatch)
- Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity (GlobeNewswire)
- Structure Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
- Lillys triple-acting obesity drug hits goal in Phase 3 trial (BioPharma Dive) +5.21%
- Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights (GlobeNewswire)
- Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions (GlobeNewswire)
Quarterly earnings
2026Q3 EPS -0.573 matched -0.573, from -0.369 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q3ended 2026-09-30 | 2026-11-09 16:30 | -0.573 | -0.573 | -1.992 | 0.00 | 0.00 | EPS 0.0% · sales - | vs 2025Q3, year-ago quarter · EPS +55.4% · sales - | 14 EPS · 10 sales | Open 0.00% vs SPY -0.63%. Close +1.49% vs SPY -0.37% |
| 2026Q2ended 2026-06-30 | 2026-08-06 16:30 | -0.487 | -0.436 | -1.464 | 0.00 | 0.00 | EPS +11.8% · sales - | vs 2025Q2, year-ago quarter · EPS +35.6% · sales - | 14 EPS · 10 sales | Open +2.24% vs SPY +0.32%. Close +0.99% vs SPY +0.61% |
| 2026Q1ended 2026-03-31 | 2026-05-07 16:30 | -0.350 | -0.351 | -1.052 | 0.00 | 0.00 | EPS -0.4% · sales - | vs 2025Q1, year-ago quarter · EPS +29.6% · sales - | 14 EPS · 11 sales | Open -2.53% vs SPY +0.46%. Close -0.13% vs SPY +0.83% |
| 2025Q4ended 2025-12-31 | 2026-02-26 16:30 | 0.182 | -0.058 | 0.560 | 21.00 | 22.87 | EPS -413.8% · sales -8.2% | vs 2024Q4, year-ago quarter · EPS -186.0% · sales - | 14 | Open -0.96% vs SPY -0.90%. Close -2.73% vs SPY -0.48% |
| 2025Q3ended 2025-09-30 | 2025-11-06 16:30 | -0.369 | -0.370 | -1.125 | 0.00 | 0.00 | EPS -0.3% · sales - | vs 2024Q3, year-ago quarter · EPS +84.2% · sales - | 14 EPS · 10 sales | Open +0.69% vs SPY -0.36%. Close -1.88% vs SPY +0.10% |
| 2025Q2ended 2025-06-30 | 2025-08-06 16:30 | -0.359 | -0.295 | -1.075 | 0.00 | 0.00 | EPS +21.7% · sales - | vs 2024Q2, year-ago quarter · EPS +98.8% · sales - | 12 EPS · 11 sales | Open +8.46% vs SPY +0.55%. Close -0.67% vs SPY -0.08% |
| 2025Q1ended 2025-03-31 | 2025-05-08 16:30 | -0.270 | -0.242 | -0.818 | 0.00 | 0.00 | EPS +11.8% · sales - | vs 2024Q1, year-ago quarter · EPS +40.0% · sales - | 11 EPS · 9 sales | Open -0.63% vs SPY +0.25%. Close -4.66% vs SPY -0.13% |
| 2024Q4ended 2024-12-31 | 2025-02-27 16:30 | -0.211 | -0.224 | -0.635 | 0.00 | 0.00 | EPS -5.8% · sales - | vs 2023Q4, year-ago quarter · EPS +40.9% · sales - | 9 EPS · 7 sales | Open +1.67% vs SPY +0.09%. Close +4.08% vs SPY +1.56% |
| 2024Q3ended 2024-09-30 | 2024-11-14 08:30 | -0.200 | -0.183 | -0.599 | 0.00 | 0.00 | EPS +9.6% · sales - | vs 2023Q3, year-ago quarter · EPS -4.8% · sales - | 8 EPS · 7 sales | Open -1.02% vs SPY +0.02%. Close +3.63% vs SPY -0.64% |
| 2024Q2ended 2024-06-30 | 2024-08-08 08:30 | -0.181 | -0.220 | -0.526 | 0.00 | 0.00 | EPS -17.9% · sales - | vs 2023Q2, year-ago quarter · EPS -9.7% · sales - | 7 | Open +2.44% vs SPY +1.01%. Close +1.35% vs SPY +2.31% |
| 2024Q1ended 2024-03-31 | 2024-05-09 16:30 | -0.193 | -0.194 | -0.558 | 0.00 | 0.00 | EPS -0.7% · sales - | vs 2023Q1, year-ago quarter · EPS -22.8% · sales - | 7 EPS · 6 sales | Open -4.48% vs SPY +0.32%. Close -7.32% vs SPY +0.13% |
| 2023Q4ended 2023-12-31 | 2024-03-08 08:30 | -0.150 | -0.186 | -0.532 | 0.00 | 0.00 | EPS -19.4% · sales - | vs 2022Q4, year-ago quarter · EPS -11.8% · sales - | 5 EPS · 4 sales | Open +2.17% vs SPY +0.13%. Close +2.36% vs SPY -0.60% |
| 2023Q3ended 2023-09-30 | 2023-11-14 16:30 | -0.210 | -0.218 | -0.623 | 0.00 | 0.00 | EPS -3.7% · sales - | - | 5 | - |
| 2023Q2ended 2023-06-30 | 2023-08-10 16:30 | -0.200 | -0.279 | -0.602 | 0.00 | 0.00 | EPS -28.2% · sales - | - | 5 EPS · 4 sales | - |
| 2023Q1ended 2023-03-31 | 2023-05-11 16:30 | -0.250 | -0.343 | -0.751 | 0.00 | 0.00 | EPS -27.0% · sales - | - | 4 EPS · 3 sales | - |
| 2022Q4ended 2022-12-31 | 2023-03-30 16:30 | -0.170 | -0.820 | -0.324 | 0.00 | 0.00 | EPS -79.3% · sales - | - | 2 | - |
Annual earnings
2025FY EPS -0.800 beat -1.061, from -0.798 a year earlier. Sales 8.33 beat 0.00, from 0.00 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | -0.104 | - | - | 732.32 | - |
| 2029FYestimate | - | -1.530 | - | - | 342.57 | - |
| 2028FYestimate | - | -2.360 | - | - | 226.7 | - |
| 2027FYestimate | - | -2.593 | - | - | 0.04 | - |
| 2026FYestimate | - | -2.119 | - | - | 0.00 | - |
| 2025FY | -0.800 | -1.061 | -0.800 | 8.33 | 0.00 | - |
| 2024FY | -0.798 | -0.811 | -2.329 | 0.00 | 0.00 | - |
| 2023FY | -0.810 | -0.830 | -2.438 | 0.00 | 0.00 | - |
| 2022FY | -5.249 | -2.493 | -1.442 | 0.00 | 0.00 | - |
Quarterly results
2026Q3 revenue 0.00, from 0.00 a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -2.12 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-11-13 | -2.12 | +0.7% |
| 2026Q4 | E | per share | 2026-11-13 | -0.67 | +1.7% |
| 2026FY | R | per share | 2026-11-13 | -2.12 | +0.7% |
| 2026Q4 | R | per share | 2026-11-13 | -0.67 | +1.7% |
| 2026Q4 | S | per share | 2026-11-10 | 0.00 | - |
| 2026Q3 | E | per share | 2026-11-09 | -0.57 | +3.3% |
| 2026Q3 | R | per share | 2026-11-09 | -0.57 | +3.3% |
| 2026FY | S | per share | 2026-11-06 | 0.00 | -100.0% |
| 2026Q3 | S | per share | 2026-11-06 | 0.00 | -100.0% |
| 2026Q2 | E | per share | 2026-08-06 | -0.41 | +6.1% |
| 2026Q2 | R | per share | 2026-08-06 | -0.42 | +7.7% |
| 2026Q2 | S | per share | 2026-07-21 | 0.00 | - |
| 2026Q1 | E | per share | 2026-05-11 | -0.35 | +0.6% |
| 2026Q1 | R | per share | 2026-05-11 | -0.35 | +0.6% |
| 2026Q1 | S | per share | 2026-05-07 | 0.00 | -100.0% |
| 2025FY | E | per share | 2026-02-27 | -0.98 | -7.8% |
| 2025Q4 | E | per share | 2026-02-27 | 0.02 | -136.0% |
| 2025FY | R | per share | 2026-02-27 | -1.20 | 0.0% |
| 2025Q4 | R | per share | 2026-02-27 | -0.05 | 0.0% |
| 2025FY | S | per share | 2026-02-26 | 0.00 | - |
| 2025Q4 | S | per share | 2026-02-26 | 0.00 | - |
| 2025Q3 | E | per share | 2025-11-10 | -0.37 | -0.2% |
| 2025Q3 | R | per share | 2025-11-06 | -0.37 | -3.3% |
| 2025Q3 | S | per share | 2025-08-17 | 0.00 | - |
| 2025Q2 | E | per share | 2025-08-07 | -0.34 | +7.1% |
| 2025Q2 | R | per share | 2025-08-07 | -0.36 | +17.4% |
| 2025Q2 | S | per share | 2025-08-07 | 0.00 | - |
| 2025Q1 | E | per share | 2025-05-13 | -0.26 | 0.0% |
| 2025Q1 | R | per share | 2025-05-08 | -0.40 | -1.2% |
| 2025Q1 | S | per share | 2025-05-08 | 0.00 | - |
| 2024FY | E | per share | 2025-02-28 | -0.79 | -0.5% |
| 2024Q4 | E | per share | 2025-02-28 | -0.21 | -1.4% |
| 2024FY | R | per share | 2025-02-27 | -0.90 | -4.3% |
| 2024Q4 | R | per share | 2025-02-27 | -0.21 | +5.0% |
| 2024FY | S | per share | 2025-02-26 | 0.00 | - |
| 2024Q4 | S | per share | 2025-02-26 | 0.00 | - |
| 2024Q3 | E | per share | 2024-11-13 | -0.19 | +1.9% |
| 2024Q3 | R | per share | 2024-11-13 | -0.17 | -3.7% |
| 2024Q3 | S | per share | 2024-09-27 | 0.00 | - |
| 2024Q2 | E | per share | 2024-08-08 | -0.19 | -13.0% |
| 2024Q2 | R | per share | 2024-08-08 | -0.18 | -11.3% |
| 2024Q2 | S | per share | 2024-05-20 | 0.00 | - |
| 2024Q1 | E | per share | 2024-05-09 | -0.19 | -6.9% |
| 2024Q1 | R | per share | 2024-05-09 | -0.20 | +8.1% |
| 2024Q1 | S | per share | 2024-04-19 | 0.00 | - |
| 2023FY | E | per share | 2024-03-07 | -0.83 | -4.9% |
| 2023FY | R | per share | 2024-03-07 | -0.73 | -12.0% |
| 2023FY | S | per share | 2024-02-26 | 0.00 | - |
Estimate history
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.439 | -1.198 | -1.442 | -2.438 | -2.329 | -2.392 | -3.9475 | - |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Shares million shares | 37 | 37 | 37 | 46 | 57 | 71 | - | 71 |
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.599 | -0.635 | -0.818 | -1.075 | -1.125 | 0.56 | -1.052 | -1.464 | -1.992 |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shares million shares | 57 | 57 | 58 | 58 | 61 | 71 | 71 | 71 | 71 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 |
|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 4.74 | 3.90+50.0% | 2.60+173.7% | 0.95+53.2% | 0.62+129.6% | 0.27+1250.0% | 0.02 |
| Gross Profit | -4.74 | -3.90 | -2.60 | -0.95 | -0.62 | -0.27 | -0.02 |
| Selling, General and Administrative Excl. Other | 447.12 | 283.67+82.2% | 155.71+53.0% | 101.74+96.1% | 51.88+38.4% | 37.48+135.6% | 15.91 |
| Research and Development | 370.83 | 225.85+107.4% | 108.87+55.4% | 70.04+93.7% | 36.15+24.0% | 29.15+135.3% | 12.39 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -451.86 | -287.57 | -158.31 | -102.69 | -52.50 | -37.75 | -15.93 |
| Interest Expense | - | - | - | - | - | 0.12 | - |
| Unusual Expense | -10.29 | -10.28 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -293.76 | -141.06 | -122.28 | -89.31 | -51.24 | -37.87 | -15.77 |
| Income Taxes | 0.77 | 0.52+67.7% | 0.31+29.2% | 0.24+1100.0% | 0.02-91.3% | 0.23+64.3% | 0.14 |
| Consolidated Net Income | -294.52 | -141.58 | -122.59 | -89.54 | -51.26 | -40.06 | -15.90 |
| Net Income From Continuing Operations | -294.52 | -141.58 | -122.59 | -89.54 | -51.26 | -40.06 | -15.90 |
| Net Income | -294.52 | -141.58 | -122.59 | -89.54 | -52.77 | -43.82 | -16.07 |
| EPS (Recurring) per share | -4.14 | -2.51 | -2.33 | -2.44 | -1.44 | -1.20 | -0.44 |
| EPS (Basic, Before Extraordinaries) per share | -3.95 | -2.39 | -2.33 | -2.44 | -1.44 | -1.20 | -0.44 |
| EPS (Diluted) per share | -3.95 | -2.39 | -2.33 | -2.44 | -1.44 | -1.20 | -0.44 |
| EBITDA | -447.12 | -283.67 | -155.71 | -101.74 | -51.88 | -37.48 | -15.91 |
| Non-Operating Income (Expense) | 147.81 | 136.23+278.1% | 36.03+169.3% | 13.38+961.9% | 1.26 | 0.00-100.0% | 0.17 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.96 | 0.00 |
| Stock Option Compensation Expense | 33.90 | 21.80+54.6% | 14.10+129.6% | 6.14+226.6% | 1.88+72.5% | 1.09+159.5% | 0.42 |
| Shares Outstanding million shares | 71.36 | 70.84+23.7% | 57.29+23.4% | 46.41+26.8% | 36.590.0% | 36.590.0% | 36.59 |
| Market Capitalization | 1,415.84 | 1,415.84-8.8% | 1,552.73+6.1% | 1,463.600.0% | 1,463.60 | - | - |
Income statement, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.84-14.3% | 1.30+52.9% | 1.22+76.8% | 1.38-26.2% | 0.98+263.0% | 0.85+269.6% | 0.69+4.5% | 1.87+567.9% |
| Gross Profit | -0.84 | -1.30 | -1.22 | -1.38 | -0.98 | -0.85 | -0.69 | -1.87 |
| Selling, General and Administrative Excl. Other | 155.91+113.8% | 117.53+68.3% | 88.43+58.8% | 85.26+89.4% | 72.91+58.7% | 69.85+111.3% | 55.70+78.0% | 45.02+45.6% |
| Research and Development | 134.91+128.4% | 100.22+82.6% | 66.71+55.4% | 68.99+106.7% | 59.07+79.7% | 54.90+149.3% | 42.93+107.9% | 33.37+65.4% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -156.75 | -118.83 | -89.65 | -86.64 | -73.89 | -70.70 | -56.39 | -46.89 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | -10.29 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -144.97 | -106.10 | -76.00 | 33.32 | -65.69 | -61.74 | -46.80 | -36.21 |
| Income Taxes | 0.17+54.5% | 0.23+64.3% | 0.19+90.0% | 0.17+21.4% | 0.11+22.2% | 0.14+180.0% | 0.10+233.3% | 0.14 |
| Consolidated Net Income | -145.14 | -106.33 | -76.19 | 33.15 | -65.80 | -61.88 | -46.90 | -36.35 |
| Net Income From Continuing Operations | -145.14 | -106.33 | -76.19 | 33.15 | -65.80 | -61.88 | -46.90 | -36.35 |
| Net Income | -145.14 | -106.33 | -76.19 | 33.15 | -65.80 | -61.88 | -46.90 | -36.35 |
| EPS (Recurring) per share | -1.99 | -1.46 | -1.05 | 0.44 | -1.12 | -1.08 | -0.82 | -0.63 |
| EPS (Basic, Before Extraordinaries) per share | -1.99 | -1.46 | -1.05 | 0.56 | -1.12 | -1.08 | -0.82 | -0.63 |
| EPS (Diluted) per share | -1.99 | -1.46 | -1.05 | 0.56 | -1.12 | -1.08 | -0.82 | -0.63 |
| EBITDA | -155.91 | -117.53 | -88.43 | -85.26 | -72.91 | -69.85 | -55.70 | -45.02 |
| Non-Operating Income (Expense) | 11.78+43.8% | 12.73+42.1% | 13.64+42.2% | 109.66+926.8% | 8.19-32.0% | 8.96+22.2% | 9.59+59.8% | 10.68+71.7% |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 9.57+70.0% | 9.49+68.0% | 8.76+97.3% | 6.08+39.4% | 5.63+23.7% | 5.65+79.9% | 4.44+116.6% | 4.36+175.9% |
| Shares Outstanding million shares | 71.36+17.6% | 71.22+23.7% | 71.07+23.5% | 70.84+23.7% | 60.68+6.0% | 57.57+0.6% | 57.54+23.4% | 57.29+23.4% |
| Market Capitalization | 1,415.84-12.2% | 3,814.29+219.6% | 3,414.38+244.3% | 4,912.96+216.4% | 1,611.87-35.8% | 1,193.31-46.7% | 991.63-50.1% | 1,552.73+6.1% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 1,446.20+63.7% | 883.52+89.1% | 467.32+414.4% | 90.84-15.3% | 107.30+186.5% | 37.45 |
| Short Term Receivables | 100.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 24.11+213.5% | 7.69+22.3% | 6.29+179.6% | 2.25+16.0% | 1.94+100.0% | 0.97 |
| Total Current Assets | 1,570.31+76.2% | 891.21+88.2% | 473.61+408.8% | 93.09-14.8% | 109.25+184.4% | 38.42 |
| Net Property, Plant & Equipment | 12.90+84.0% | 7.01-16.1% | 8.36+548.1% | 1.29-27.9% | 1.79+539.3% | 0.28 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.72-85.9% | 5.11+12675.0% | 0.04-98.8% | 3.46+3045.5% | 0.11+1000.0% | 0.01 |
| Total Assets | 1,583.92+75.3% | 903.33+87.4% | 482.02+392.6% | 97.85-12.0% | 111.15+187.2% | 38.70 |
| Short Term Debt Incl. Current Port. of LT Debt | 2.88+69.4% | 1.70+18.1% | 1.44+453.8% | 0.26-25.7% | 0.35+133.3% | 0.15 |
| Accounts Payable | 13.86+72.8% | 8.02+69.2% | 4.74-21.1% | 6.01+72.7% | 3.48+127.5% | 1.53 |
| Income Tax Payable | - | - | 0.36+111.8% | 0.17-26.1% | 0.23+64.3% | 0.14 |
| Other Current Liabilities | 46.54+77.0% | 26.30+44.5% | 18.20+177.0% | 6.57+43.1% | 4.59+273.2% | 1.23 |
| Total Current Liabilities | 63.29+75.7% | 36.02+45.6% | 24.74+90.2% | 13.01+50.2% | 8.66+184.9% | 3.04 |
| Long Term Debt | 3.61+67.1% | 2.16-46.1% | 4.01 | 0.00-100.0% | 0.27+107.7% | 0.13 |
| Provision for Risks Charges | 0.00-100.0% | 0.300.0% | 0.30 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.65 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 67.54+75.5% | 38.49+32.5% | 29.05+123.3% | 13.01+45.7% | 8.93+181.7% | 3.17 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00-100.0% | 199.98+19.8% | 166.96+187.9% | 58.00 |
| Common Equity | 1,516.38+75.3% | 864.84+90.9% | 452.97 | -115.14 | -64.73 | -22.47 |
| Total Shareholders Equity | 1,516.38+75.3% | 864.84+90.9% | 452.97+433.9% | 84.84-17.0% | 102.22+187.7% | 35.53 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 1,516.38+75.3% | 864.84+90.9% | 452.97+433.9% | 84.84-17.0% | 102.22+187.7% | 35.53 |
| Total Liabilities & Stockholders Equity | 1,583.92+75.3% | 903.33+87.4% | 482.02+392.6% | 97.85-12.0% | 111.15+187.2% | 38.70 |
| Book Value Per Share per share | 21.41+41.8% | 15.10+54.7% | 9.76 | -3.15 | -1.77 | -0.61 |
| Tangible Book Value Per Share per share | 21.41+41.8% | 15.10+54.7% | 9.76 | -3.15 | -1.77 | -0.61 |
| Full-Time Employees people | 220+35.0% | 163+75.3% | 93+36.8% | 68 | - | - |
| Price to Book Ratio ratio | 1.16 | 1.73 | 7.58 | 7.58 | - | - |
| Return on Assets % | -11.38 | -17.70 | -30.88 | -49.05 | -53.47 | - |
| Return on Equity % | -11.89 | -18.60 | -33.30 | -54.81 | -58.16 | - |
| Return on Invested Capital % | -9.31 | -14.14 | -19.59 | -60.42 | -39.09 | -44.59 |
| Quick Ratio ratio | 24.81 | 24.74 | 19.14 | 7.16 | 12.62 | 12.64 |
| Current Ratio ratio | 24.81 | 24.74 | 19.14 | 7.16 | 12.62 | 12.64 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 |
|---|---|---|---|---|---|---|---|
| Net Income | -294.60 | -141.58 | -122.59 | -89.54 | -51.26 | -38.10 | -15.90 |
| Depreciation | 4.74 | 3.90+50.0% | 2.60+173.7% | 0.95+53.2% | 0.62+129.6% | 0.27+1250.0% | 0.02 |
| Other Funds (Non Cash) | 22.27 | 3.16+857.6% | 0.33-85.1% | 2.21+37.3% | 1.61+3.2% | 1.56+147.6% | 0.63 |
| Funds from Operations | -267.59 | -134.51 | -119.66 | -86.38 | -49.03 | -36.27 | -15.26 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -4.12 | -88.27-3072.1% | 2.97-57.3% | 6.96+135.1% | 2.96-27.3% | 4.07+328.4% | 0.95 |
| Cash from Operating Activities | -271.71 | -222.79 | -116.69 | -79.42 | -46.07 | -32.20 | -14.31 |
| Capital Expenditures | -6.30 | -3.62 | -1.29 | -2.17 | -0.15 | -1.21 | -0.02 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | -315.37 | 83.38 | -357.80 | -265.94 | -61.88-424.1% | 19.09 | -21.16 |
| Purchase of Investments | -871.22 | -548.83 | -702.87 | -416.99 | -123.31 | -4.22 | -21.16 |
| Sale Or Maturity of Investments | 555.84 | 632.21+83.2% | 345.07+128.4% | 151.05+145.9% | 61.43+163.5% | 23.31 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 5.11 | 10.28 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -316.56 | 90.03 | -359.09 | -268.11 | -62.03-446.9% | 17.88 | -21.18 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 713.08 | 767.18+48.3% | 517.32+9.4% | 472.68+1401.0% | 31.49-69.5% | 103.39+299.5% | 25.88 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 713.08 | 767.18+48.3% | 517.32+9.4% | 472.68+1400.6% | 31.50-69.5% | 103.39+299.5% | 25.88 |
| Proceedsfrom Stock Options | 706.20 | 762.64+48.0% | 515.46+9.2% | 471.89+1400.0% | 31.46-69.6% | 103.38+299.5% | 25.88 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | -5.11 | -2.64 | -1.80 | -21.55 | -2.51 | 0.00 | 0.00 |
| Other Financing Activities Uses | -5.11 | -2.64 | -1.80 | -21.55 | -2.51 | 0.00 | 0.00 |
| Cash from Financing Activities | 707.97 | 764.53+48.3% | 515.52+14.3% | 451.14+1456.7% | 28.98-72.0% | 103.39+299.5% | 25.88 |
| Net Change in Cash | 119.70 | 631.78+1489.8% | 39.74-61.6% | 103.61 | -79.12-188.8% | 89.07 | -9.61 |
| Free Cash Flow | -278.01 | -226.41 | -117.99 | -81.58 | -46.22 | -33.41 | -14.33 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | - | - | - |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 1,239.95+55.2% | 1,342.70+70.7% | 1,458.55+74.3% | 1,446.20+63.7% | 799.04-12.7% | 786.51-15.2% | 836.89+91.8% | 883.52+89.1% |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 100.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 35.15+134.6% | 29.37+129.5% | 32.09+151.9% | 24.11+213.5% | 14.98+79.0% | 12.80+21.9% | 12.74-1.3% | 7.69+22.3% |
| Total Current Assets | 1,275.10+56.6% | 1,372.07+71.7% | 1,490.64+75.4% | 1,570.31+76.2% | 814.02-11.9% | 799.31-14.8% | 849.63+89.1% | 891.21+88.2% |
| Net Property, Plant & Equipment | 16.84+45.9% | 12.39+13.3% | 11.97+10.5% | 12.90+84.0% | 11.54+49.1% | 10.94+44.3% | 10.83+38.5% | 7.01-16.1% |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 42.45+543.2% | 41.00+561.3% | 5.56-8.9% | 0.72-85.9% | 6.60+262.6% | 6.20+238.8% | 6.10+12100.0% | 5.11+12675.0% |
| Total Assets | 1,334.39+60.4% | 1,425.46+74.6% | 1,508.17+74.0% | 1,583.92+75.3% | 832.16-10.8% | 816.46-13.8% | 866.56+89.5% | 903.33+87.4% |
| Short Term Debt Incl. Current Port. of LT Debt | 2.76-1.4% | 2.60-2.3% | 2.61+5.7% | 2.88+69.4% | 2.80+63.7% | 2.66+63.2% | 2.47+54.4% | 1.70+18.1% |
| Accounts Payable | 33.88+90.3% | 11.13+23.8% | 7.82-10.2% | 13.86+72.8% | 17.80+110.7% | 8.99+306.8% | 8.71+33.2% | 8.02+69.2% |
| Other Current Liabilities | 70.46+90.8% | 52.39+91.3% | 46.55+83.9% | 46.54+77.0% | 36.93+59.6% | 27.38+45.8% | 25.31+67.1% | 26.30+44.5% |
| Total Current Liabilities | 107.10+86.2% | 66.12+69.4% | 56.99+56.2% | 63.29+75.7% | 57.53+72.1% | 39.03+72.2% | 36.49+54.7% | 36.02+45.6% |
| Long Term Debt | 4.06-5.4% | 3.63-27.5% | 3.18-37.9% | 3.61+67.1% | 4.29+60.7% | 5.01+64.3% | 5.12+45.5% | 2.16-46.1% |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.31+3.3% | 0.300.0% |
| Other Liabilities | 1.38+318.2% | 1.27+296.9% | 0.86 | 0.65 | 0.33 | 0.32 | 0.00 | 0.00 |
| Total Liabilities | 112.55+81.1% | 71.01+60.1% | 61.03+45.6% | 67.54+75.5% | 62.14+70.6% | 44.36+70.6% | 41.91+52.9% | 38.49+32.5% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 1,221.84+58.7% | 1,354.45+75.4% | 1,447.14+75.5% | 1,516.38+75.3% | 770.02-14.1% | 772.09-16.2% | 824.65+91.9% | 864.84+90.9% |
| Total Shareholders Equity | 1,221.84+58.7% | 1,354.45+75.4% | 1,447.14+75.5% | 1,516.38+75.3% | 770.02-14.1% | 772.09-16.2% | 824.65+91.9% | 864.84+90.9% |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 1,221.84+58.7% | 1,354.45+75.4% | 1,447.14+75.5% | 1,516.38+75.3% | 770.02-14.1% | 772.09-16.2% | 824.65+91.9% | 864.84+90.9% |
| Total Liabilities & Stockholders Equity | 1,334.39+60.4% | 1,425.46+74.6% | 1,508.17+74.0% | 1,583.92+75.3% | 832.16-10.8% | 816.46-13.8% | 866.56+89.5% | 903.33+87.4% |
| Book Value Per Share per share | 17.12+34.9% | 19.02+41.8% | 20.36+42.1% | 21.41+41.8% | 12.69-19.0% | 13.41-16.7% | 14.33+55.4% | 15.10+54.7% |
| Tangible Book Value Per Share per share | 17.12+34.9% | 19.02+41.8% | 20.36+42.1% | 21.41+41.8% | 12.69-19.0% | 13.41-16.7% | 14.33+55.4% | 15.10+54.7% |
| Full-Time Employees people | 281+28.9% | 281+41.2% | 233+27.3% | 220+35.0% | 218+47.3% | 199+46.3% | 183+64.9% | 163+75.3% |
| Price to Book Ratio ratio | 1.16 | 2.64 | 2.25 | 5.48 | 2.09 | 1.45 | 1.15 | 1.73 |
| Return on Assets % | -27.19 | -19.20 | -14.38 | -11.37 | -23.90 | -20.34 | -21.68 | -17.70 |
| Return on Equity % | -29.57 | -20.24 | -15.03 | -11.88 | -25.31 | -21.19 | -22.88 | -18.61 |
| Return on Invested Capital % | -11.84 | -7.83 | -5.25 | 2.18 | -8.50 | -7.96 | -5.65 | -4.19 |
| Quick Ratio ratio | 11.91 | 20.75 | 26.16 | 24.81 | 14.15 | 20.48 | 23.29 | 24.74 |
| Current Ratio ratio | 11.91 | 20.75 | 26.16 | 24.81 | 14.15 | 20.48 | 23.29 | 24.74 |
Cash flow, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -145.07 | -106.31 | -76.19 | 32.97 | -65.79 | -61.86 | -46.90 | -36.44 |
| Depreciation | 0.84-14.3% | 1.30+52.9% | 1.22+76.8% | 1.38-26.6% | 0.98 | 0.85+28.8% | 0.69+4.5% | 1.88+571.4% |
| Other Funds (Non Cash) | 9.54+125.5% | 9.27+191.5% | 8.43+1070.8% | -4.97 | 4.23+258.5% | 3.18+214.9% | 0.72 | -1.33 |
| Funds from Operations | -134.69 | -95.74 | -66.55 | 29.39 | -60.58 | -57.83 | -45.49 | -35.90 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 32.77+243.9% | -24.64-900.0% | 81.83 | -94.08 | 9.53-30.4% | 3.08 | -6.81 | -0.54-119.8% |
| Cash from Operating Activities | -101.92 | -120.38 | 15.28 | -64.69 | -51.05 | -54.75 | -52.30 | -36.44 |
| Capital Expenditures | -3.65 | 0.04 | -1.19 | -1.50 | -1.57 | -0.23 | -0.31 | -0.02 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 54.10 | 75.06+52.2% | -497.24-1545.5% | 52.70+57.3% | -53.05 | 49.33 | 34.40+2077.2% | 33.51 |
| Purchase of Investments | -83.50 | -44.14 | -649.40 | -94.17 | -249.22 | -89.16 | -116.27 | -131.97 |
| Sale Or Maturity of Investments | 137.61-29.9% | 119.20-13.9% | 152.16+1.0% | 146.88-11.2% | 196.17+193.9% | 138.49+74.4% | 150.67+350.4% | 165.47+188.9% |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00-100.0% | 0.00 | 0.00 | 5.11 | 5.17 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 50.45 | 75.10+53.0% | -498.43-1562.5% | 56.31+68.1% | -49.46 | 49.10 | 34.08+2300.0% | 33.49 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 1.24-97.8% | 2.09+301.9% | 0.83-14.4% | 708.92+236206.7% | 56.78+3300.0% | 0.52-99.9% | 0.97+29.3% | 0.30-99.9% |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 1.24-97.8% | 2.09+301.9% | 0.83-14.4% | 708.92+236206.7% | 56.78+3300.0% | 0.52-99.9% | 0.97+29.3% | 0.30-99.9% |
| Proceedsfrom Stock Options | -0.00-100.0% | 0.00 | -0.04 | 706.24+1008814.3% | 56.40+4340.9% | 0.00-100.0% | 0.00 | 0.07-100.0% |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | -0.50 | 0.00 | -2.58 | -2.03 | -0.46 | -0.00 | -0.16 | 0.00 |
| Other Financing Activities Uses | -0.50 | 0.00 | -2.58 | -2.03 | -0.46 | -0.00 | -0.16 | 0.00 |
| Cash from Financing Activities | 0.74-98.7% | 2.09+301.9% | -1.75-316.0% | 706.89+235530.0% | 56.31+10941.2% | 0.52-99.9% | 0.81+15.7% | 0.30-99.9% |
| Net Change in Cash | -50.73 | -43.18 | -484.90 | 698.51 | -44.19 | -5.13-101.8% | -17.41 | -2.65-103.3% |
| Free Cash Flow | -105.57 | -120.34 | 14.09 | -66.19 | -52.62 | -54.98 | -52.62 | -36.45 |
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 8.53% | 5.9M | 69.5M | 1.09M |
| 2026-10-15 | 10.29% | 7.1M | 69.5M | 1.02M |
| 2026-09-30 | 10.86% | 7.5M | 69.5M | 888.51K |
| 2026-09-15 | 9.51% | 6.6M | 69.5M | 801.16K |
| 2026-08-31 | 8.43% | 5.9M | 69.5M | 733.47K |
| 2026-08-14 | 8.75% | 6.1M | 69.5M | 711.75K |
| 2026-07-31 | 8.70% | 6.0M | 69.6M | 746.66K |
| 2026-07-15 | 8.94% | 6.2M | 69.4M | 814.35K |
| 2026-06-30 | 8.83% | 6.1M | 69.4M | 877.47K |
| 2026-06-15 | 8.51% | 5.9M | 69.2M | 915.18K |
| 2026-05-29 | 8.03% | 5.6M | 69.4M | 902.49K |
| 2026-05-15 | 8.14% | 5.7M | 69.4M | 929.71K |
| 2026-04-30 | 8.61% | 6.0M | 69.3M | 972.83K |
| 2026-04-15 | 8.89% | 6.1M | 69.1M | 1.00M |
| 2026-03-31 | 8.33% | 5.8M | 69.1M | 1.05M |
| 2026-03-13 | 7.62% | 5.3M | 69.1M | 1.04M |
| 2026-02-27 | 7.57% | 5.2M | 69.1M | 1.49M |
| 2026-02-13 | 7.16% | 4.9M | 68.9M | 1.61M |
| 2026-01-30 | 7.43% | 5.1M | 69.1M | 1.60M |
| 2026-01-15 | 9.05% | 6.2M | 69.1M | 1.53M |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 12.50 | 5.40 | 9.60 | 0.00 | 5.657 | 0.00 | 0.00 | 0.910 | -0.084 | 0.005 |
| call | 15.00 | 2.90 | 7.00 | 0.00 | 4.144 | 0.00 | 0.00 | 0.873 | -0.075 | 0.006 |
| call | 17.50 | 1.10 | 4.70 | 0.00 | 3.143 | 0.00 | 0.00 | 0.767 | -0.079 | 0.009 |
| call | 20.00 | 0.70 | 2.05 | 1.30 | 1.828 | 34.00 | 1.00 | 0.536 | -0.123 | 0.012 |
| call | 22.50 | 0.00 | 0.55 | 1.12 | 1.232 | 203 | 0.00 | 0.273 | -0.077 | 0.010 |
| call | 25.00 | 0.00 | 0.70 | 0.35 | 1.724 | 240 | 1.00 | 0.216 | -0.094 | 0.009 |
| call | 27.50 | 0.00 | 1.10 | 0.04 | 2.125 | 42.00 | 5.00 | 0.187 | -0.106 | 0.008 |
| call | 30.00 | 0.00 | 1.20 | 0.10 | 2.466 | 151 | 0.00 | 0.168 | -0.115 | 0.007 |
| call | 32.50 | 0.00 | 3.40 | 0.10 | 2.765 | 67.00 | 0.00 | 0.155 | -0.123 | 0.007 |
| call | 35.00 | 0.00 | 3.40 | 2.25 | 3.031 | 202 | 0.00 | 0.146 | -0.129 | 0.007 |
| call | 37.50 | 0.00 | 3.40 | 0.50 | 3.270 | 70.00 | 0.00 | 0.138 | -0.134 | 0.006 |
| call | 40.00 | 0.00 | 3.40 | 0.04 | 3.488 | 324 | 0.00 | 0.132 | -0.139 | 0.006 |
| call | 42.50 | 0.00 | 3.40 | 0.00 | 3.688 | 0.00 | 0.00 | 0.127 | -0.143 | 0.006 |
| call | 45.00 | 0.00 | 3.40 | 0.06 | 3.873 | 41.00 | 0.00 | 0.123 | -0.147 | 0.006 |
| call | 47.50 | 0.00 | 3.40 | 0.05 | 4.044 | 32.00 | 0.00 | 0.120 | -0.150 | 0.006 |
| call | 50.00 | 0.00 | 3.40 | 0.01 | 4.204 | 127 | 0.00 | 0.117 | -0.153 | 0.006 |
| call | 55.00 | 0.00 | 3.40 | 0.01 | 4.496 | 16.00 | 0.00 | 0.112 | -0.159 | 0.006 |
| put | 12.50 | 0.00 | 3.40 | 0.00 | 2.771 | 0.00 | 0.00 | -0.090 | -0.083 | 0.005 |
| put | 15.00 | 0.00 | 0.75 | 0.00 | 1.914 | 0.00 | 0.00 | -0.127 | -0.074 | 0.006 |
| put | 17.50 | 0.10 | 0.60 | 0.20 | 1.371 | 414 | 1.00 | -0.233 | -0.077 | 0.009 |
| put | 20.00 | 0.70 | 1.75 | 1.05 | 1.445 | 712 | 22.00 | -0.464 | -0.120 | 0.012 |
| put | 22.50 | 1.45 | 3.70 | 3.20 | 1.724 | 39.00 | 0.00 | -0.727 | -0.074 | 0.010 |
| put | 25.00 | 3.20 | 6.60 | 6.80 | 2.653 | 36.00 | 0.00 | -0.784 | -0.091 | 0.009 |
| put | 27.50 | 5.70 | 9.00 | 7.73 | 3.015 | 50.00 | 0.00 | -0.813 | -0.103 | 0.008 |
| put | 30.00 | 8.10 | 12.30 | 10.98 | 4.174 | 24.00 | 0.00 | -0.832 | -0.112 | 0.007 |
| put | 32.50 | 10.50 | 14.80 | 10.55 | 4.530 | 34.00 | 0.00 | -0.845 | -0.119 | 0.007 |
| put | 35.00 | 13.00 | 17.30 | 4.10 | 4.748 | 10.00 | 0.00 | -0.854 | -0.125 | 0.007 |
| put | 37.50 | 15.50 | 19.80 | 13.70 | 5.029 | 1.00 | 0.00 | -0.862 | -0.130 | 0.006 |
| put | 40.00 | 18.00 | 22.30 | 0.00 | 5.285 | 0.00 | 0.00 | -0.868 | -0.134 | 0.006 |
| put | 42.50 | 20.50 | 24.80 | 15.49 | 5.518 | 1.00 | 0.00 | -0.873 | -0.138 | 0.006 |
| put | 45.00 | 23.00 | 27.30 | 0.00 | 5.734 | 0.00 | 0.00 | -0.877 | -0.142 | 0.006 |
| put | 47.50 | 25.50 | 29.80 | 0.00 | 5.934 | 0.00 | 0.00 | -0.880 | -0.145 | 0.006 |
| put | 50.00 | 28.00 | 32.30 | 0.00 | 6.120 | 0.00 | 0.00 | -0.883 | -0.148 | 0.006 |
| put | 55.00 | 33.00 | 37.30 | 0.00 | 6.458 | 0.00 | 0.00 | -0.888 | -0.153 | 0.006 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-09 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-11-09 | 8-K | Current report | 2026-11-09 | SEC |
| 2026-11-05 | SCHEDULE 13G/A | SEC | ||
| 2026-09-22 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-18 | SEC |
| 2026-09-21 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-08 | 8-K | Current report | 2026-09-08 | SEC |
| 2026-09-02 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-01 | SEC |
| 2026-08-19 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-18 | SEC |
| 2026-08-07 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-06 | SEC |
| 2026-08-07 | 3 | Initial statement of beneficial ownership of securities | 2026-08-06 | SEC |
| 2026-08-06 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-06 | 8-K | Current report | 2026-08-06 | SEC |
| 2026-08-06 | SCHEDULE 13G/A | SEC | ||
| 2026-08-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-04 | SEC |
| 2026-07-24 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-22 | SEC |
| 2026-07-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-14 | SEC |
| 2026-06-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-25 | SEC |
| 2026-06-25 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-06-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-17 | SEC |
| 2026-06-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-17 | SEC |
| 2026-06-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-17 | SEC |
| 2026-06-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-17 | SEC |
| 2026-06-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-17 | SEC |
| 2026-06-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-17 | SEC |
| 2026-06-18 | 8-K | Current report | 2026-06-17 | SEC |
| 2026-05-07 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-03-31 | SEC |
| 2026-05-07 | 8-K | Current report | 2026-05-07 | SEC |
| 2026-05-07 | 424B5 | SEC | ||
| 2026-04-23 | 4 | Statement of changes in beneficial ownership of securities | 2026-04-15 | SEC |
| 2026-04-23 | 3 | Initial statement of beneficial ownership of securities | 2026-04-15 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| FMR LLC | 13.12% |
| WELLINGTON MANAGEMENT GROUP LLP | 10.38% |
| Avoro Capital Advisors LLC | 9.22% |
| Jupiter Topco LLC | 7.32% |
| Deep Track Capital, LP | 6.67% |
| BVF INC/IL | 4.74% |
| MORGAN STANLEY | 3.95% |
| ORBIMED ADVISORS LLC | 3.11% |
| RTW INVESTMENTS, LP | 2.26% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2.19% |
Funds
| Fund | % owned |
|---|---|
| VANGUARD HEALTH CARE FUND | 4.61% |
| Heritage Fund | 1.36% |
| Fidelity Advisor Growth Opportunities Fund | 1.03% |
| Global Emerging Markets Fund | 0.88% |
| Janus Henderson Global Life Sciences Fund | 0.77% |
| Select Biotechnology Portfolio | 0.76% |
| Fidelity Advisor Biotechnology Fund | 0.74% |
| Select Health Care Portfolio | 0.70% |
| Janus Henderson Triton Fund | 0.66% |
| Fidelity Stock Selector Small Cap Fund | 0.61% |
OakChart. GPCR. Cached 15 minutes. Terms